Jones R N, Barry A L
Clinical Microbiology Institute, Tualatin, Oregon 97062.
Diagn Microbiol Infect Dis. 1988 Nov;11(3):159-62. doi: 10.1016/0732-8893(88)90018-1.
MDL 19,592, a semisynthetic oral cephalosporin, has an antimicrobial spectrum principally directed against Gram-positive cocci (MIC50, 0.25-4 micrograms/ml), Branhamella catarrhalis (MIC50, 1-2 micrograms/ml), and pathogenic Neisseria spp. such as meningococci (MIC50, 4 micrograms/ml). Enterobacteriaceae, enterococci, Pseudomonas spp., Corynebacterium jeikeium, and Acinetobacter calcoaceticus strains had MDL 19,592 MIC50 of greater than or equal to 32 micrograms/ml. Although MDL 19,592 generally had a spectrum most similar to cefadroxil, it could not be represented by the cephalothin susceptibility test because of low predictive values and MIC correlations.
MDL 19,592是一种半合成口服头孢菌素,其抗菌谱主要针对革兰氏阳性球菌(MIC50为0.25 - 4微克/毫升)、卡他布兰汉菌(MIC50为1 - 2微克/毫升)以及致病性奈瑟菌属,如脑膜炎球菌(MIC50为4微克/毫升)。肠杆菌科、肠球菌、假单胞菌属、杰氏棒状杆菌和醋酸钙不动杆菌菌株的MDL 19,592 MIC50大于或等于32微克/毫升。尽管MDL 19,592的抗菌谱通常与头孢羟氨苄最为相似,但由于预测值和MIC相关性较低,无法通过头孢菌素敏感性试验来体现。